AA股股回回调调是是不不是是上上车车机机会会？？ 22002255年年77月月2288日日--22002255年年88月月11日日基基金金投投顾顾观观点点 本周A股、港股承压，债市震荡，黄金和美股小幅收跌。具体来看，本周市场有以下几个重要 方面 ： 本周A股、港股普遍承压，港股波动高于A股。虽然市场承压，但从成交量看，活跃度仍在高 位，本周内沪深两市日均成交额达到1.78万亿元，相比上周下降330亿元，变化幅度并不明 显。申万一级行业上，医药生物、通信、传媒行业领涨，领涨行业主要集中于景气成长方 向，煤炭、有色金属、房地产行业领跌，领跌行业主要集中于经济周期敏感度高的方向。 02 债市方面，本周资金面整体均衡，债市分化，利率债上涨，信用债小幅下跌，预计纯债基金 收益小幅收正。政策面上，本周召开政治局会议，对于经济定调偏乐观，短期工作重点 在"制定十五五"规划。资金面上，本周资金面整体均衡，对债市影响偏中性。基本面上，本 周公布制造业PMI数据仍位于荣枯线以下，对债市偏利好。 03 商品方面，COMEX黄金本周周度震荡走平，周三受美联储议息会议即将到来的影响，市场 避险情绪抬升，COMEX黄金高开，后结果符合市 ...

Group 1 - The core viewpoint of the article emphasizes that macroeconomic policies in July focused on both supply and demand, exceeding market expectations, which is expected to improve the mid-term supply-demand structure and corporate profitability [5][10] - The total investment of 1.2 trillion yuan for the "Yaxia" hydropower station project is expected to drive national water conservancy investment by 3.5-6.2% in 2024, further enhancing economic growth expectations [5][10] - The implementation of the childcare subsidy policy starting January 1, 2025, reflects the government's attention to factors affecting long-term economic growth, with a current standard of 3,600 yuan per child per year [11] Group 2 - The U.S. tariff situation has gradually eased since May, with significant progress in trade negotiations between the U.S. and other countries, although future negotiations may face challenges [6][13] - The equity risk premium for the CSI 300 index was recorded at 6.30 at the end of July, continuing to decline and remaining below the historical average [6][16] - In July 2025, the number of stocks with over 20% gains decreased by 3% compared to the previous month, indicating a divergence between the significant increase in trading volume and the marginal decline in profit-making effects [6][17] Group 3 - The Shanghai Composite Index attempted to break through the upper resistance level but faced technical pressure, indicating a need for consolidation before further upward movement [7][19] - The CSI 300 index reached a new high for the year in July but did not touch the high from November of the previous year, suggesting it remains in a volatile market pattern [7][23]

Core Viewpoint - The recognition of Shenyin Wanguo Futures for its "Insurance + Futures" projects highlights the effectiveness of financial innovation in supporting agriculture and rural development, showcasing the company's commitment to national strategies and social responsibility [2][4]. Group 1: Awards and Recognition - Shenyin Wanguo Futures received multiple honors from Zhengzhou Commodity Exchange for its "Xinjiang Maigaiti Red Dates" and "Shaanxi Fu County Apples" projects, including the 2024 Annual Excellent Project, Best Promotion Award, and Best Compensation Award [2]. - The projects were recognized for their innovative design, significant benefits to agriculture, exemplary demonstration effects, and solid risk management capabilities [2][4]. Group 2: Impact on Agriculture - The awards reflect the successful implementation of the "Insurance + Futures" model in managing agricultural risks and ensuring farmers' income [4]. - These initiatives are seen as a practical embodiment of the national strategy for financial services to the real economy and the comprehensive promotion of rural revitalization [3][4].

Market Review - The market has shown a continued upward trend over the past two weeks, with increased trading volume and a recovery in investor sentiment, indicating a gradual emergence of a bull market [2] - Key sectors driving this trend include cyclical stocks, securities, and pharmaceuticals, while large-cap stocks have performed strongly, and small-cap stocks have shown average performance [2] - The overall market capacity is substantial, and while trading volume is increasing, it is not sufficient to sustain a broad market rally, leading to a structural bull market characteristic [2] - Optimism remains for the future market, although some pullbacks are expected during the upward movement, which may not alter the overall upward trend [2]

Core Viewpoint - The article discusses the establishment and operational guidelines of the "Science and Technology Innovation Growth Layer" on the STAR Market, aimed at supporting unprofitable but promising technology companies [5][19]. Group 1: Introduction to the Science and Technology Innovation Growth Layer - The Science and Technology Innovation Growth Layer was officially launched on July 13, 2025, by the Shanghai Stock Exchange, with the goal of fostering the development of technology enterprises that are not yet profitable but have significant growth potential [5]. - This layer is designed to enhance the inclusivity for technology companies with bright prospects, allowing them to access capital markets more easily [9][17]. Group 2: Access and Participation Guidelines - Investors who already have STAR Market trading permissions and have a risk tolerance assessment result of C4 (active) or above can trade stocks or depositary receipts listed after the new regulations on the Science and Technology Innovation Growth Layer, provided they sign a risk disclosure statement [7][11]. - For investors who have not yet opened STAR Market trading permissions, they must first meet the basic requirements and then sign the risk disclosure statement to participate in trading [11][12]. Group 3: Eligibility Requirements for Investors - To open trading permissions for the STAR Market, individual investors must have an average daily asset of no less than RMB 500,000 in their securities and funds accounts over the past 20 trading days, excluding funds and securities borrowed through margin trading [12]. - Investors must have at least 24 months of trading experience and pass a knowledge test regarding STAR Market trading risks [12]. Group 4: Identification and Labeling of Stocks - Stocks of companies listed on the Science and Technology Innovation Growth Layer will have a "U" identifier to indicate their unprofitable status, with new registrations labeled as "成" and existing stocks labeled as "成1" to differentiate between new and existing stocks [17].

Core Viewpoint - The article emphasizes the importance of enhancing the diverse social value of listed companies, focusing on integrity, green transformation, and cultural leadership as key components of their societal impact [6][7]. Group 1: Diverse Social Value of Listed Companies - Listed companies play a significant role as influential social entities, with their social behavior being a focal point of market attention [7]. - The evaluation of listed companies' social value is multi-dimensional, involving various stakeholders such as financial investors, employees, consumers, and non-profit organizations [7][8]. - The social value of listed companies is interconnected, with credit value serving as the foundation, green value guiding sustainable practices, cultural value shaping product and service orientation, and strategic value aligning with national development goals [9][6]. Group 2: Enhancing Credit Value - Credit value reflects a company's ability and willingness to fulfill commitments, impacting its reputation and operational stability [11]. - Companies should prioritize integrity in their operations, recognizing the importance of credit management and establishing systems to enhance credit ratings [12][13]. - High-quality information disclosure is crucial for improving credit value, with companies encouraged to adopt transparent practices and utilize various communication channels [14][15]. Group 3: Promoting Green Value - Green value is defined as the ability of listed companies to transform ecological responsibilities into sustainable competitive advantages through green technologies [16]. - The relationship between green ecological value and market performance is significant, with compliance to environmental standards becoming a prerequisite for market participation [17][18]. - Companies are encouraged to integrate green technology innovations into their strategies, balancing short-term costs with long-term benefits [19][20]. Group 4: Cultural Value Enhancement - Cultural value encompasses a company's ability to guide social cultural development and meet the high-quality living demands of residents [23]. - Companies face challenges in aligning their products and services with consumer needs, often lacking in high-quality offerings and cultural integration [24][26]. - To enhance cultural value, companies should focus on innovative supply strategies that resonate with consumer aspirations and cultural identity [27][28]. Group 5: Strategic Value Integration - Strategic value involves aligning company operations with national development goals, leveraging core technologies and regional resources [30][31]. - Companies are urged to proactively integrate their strategies with national initiatives, identifying new opportunities for growth [32][33]. - The strategic value of companies is linked to their ability to access and utilize government resources and support for development [33].

首先，上周市场围绕中美瑞典经贸会谈和国内下半年经济预期展开。美国对等关税事件在 5 月之后逐渐走向缓和。一方面美国同英国、欧盟和其他国 家的关税逐渐确定下来。另一方面，中美经历了三轮经贸谈判，分歧得到一定的管控，非关税壁垒措施也有所减少或者取消。这些都成为近几个月市场回 升的主要推动因素。当然，随着谈判的深入，未来要再取得更大的成果，必定面临更大的困难和波折，特别是在美国基本面逐步稳定下来，美元指数开始 回升的阶段。下半年国内经济增速略有回落是市场共识，但政策维稳工具丰富，将灵活应对各种挑战也是一致预期。 上周，两市先涨后跌，日均成交减少。沪指上周连续上涨后迎来调整，周三盘中创出年内高点后快速调整，周五收盘跌破 5 天和 10天均线，收盘于 20 天均线上方。深圳成指同步调整，也在 20 天均线上方止跌。量能方面，上周两市日均量能不到 18000 亿元，较上周出现小幅萎缩。上周市场热点主要 集中在医药和 TMT 行业。投资风格方面，中小盘相对抗跌。 风险提示：国际地缘、贸易冲突超出预期；全球金融市场风险暴露；国内上市公司业绩增速回落超预期；全球经济衰退超预期。 从市场运行节奏看，沪指在冲击去年高点时遇阻回落， ...

本内容最终解释权归申万宏源证券有限公司所有。 免责声明 ...

Core Viewpoint - The A-share market experienced a significant adjustment but did not show signs of panic selling, indicating a gradual increase in market confidence towards an upward trend [1] Market Overview - On Thursday, the A-share index saw a notable decline, with the Shanghai Composite Index dropping over 1% and more than 4200 stocks declining, marking the largest single-day adjustment since April 7 [1] - The trading volume reached 1.93 trillion, which is considered normal, suggesting that there was no panic selling [1] - The index has officially broken through the high point of November 8, 2024, indicating the end of the sideways movement since the fourth quarter of 2024 [1] - Concerns regarding trade conflicts have eased, and with the policy window approaching in July, the market is expected to maintain a slow upward trend amidst fluctuations [1] Future Outlook - There are multiple catalysts in various industries, leading to a more optimistic outlook for the market [2] - After the index surpassed 3500 points, two potential paths are identified: continuing the upward trend to challenge the high of October 8, 2024, or consolidating before attempting to break the 3674 high [2] - Three conditions are necessary for a direct challenge to previous highs: implementation of fiscal stimulus policies, continued global environment easing, and sustained increase in trading volume [2] Sector Highlights - The technology sector is expected to gain momentum in August, driven by various catalysts [3] - The AI conference has introduced new hotspots, indicating potential opportunities in the AI sector [3] - The trend towards domestic robotization is expected to continue, with opportunities arising in related components such as sensors and controllers [3] - The semiconductor industry remains a focus, particularly in domestic equipment, wafer manufacturing, and IC design [3] - The military industry is anticipated to see a rebound in orders by 2025, with signs of recovery in quarterly reports [3] - The innovative drug sector is expected to reach a turning point in fundamentals after a prolonged adjustment period [3] Market Review - Despite the rapid adjustment, the market maintains an upward trend, and the consolidation phase is seen as beneficial for the mid-term outlook [4] - Most sectors experienced declines, with only the computer and communication sectors showing gains, while sectors like steel, non-ferrous metals, and real estate faced significant losses [4]

Core Viewpoint - The Hong Kong innovative drug sector has shown strong performance in 2025, with the Hang Seng Innovative Drug Index increasing by 81.40%, significantly outperforming major Hong Kong indices [1] Group 1: Definition and Growth of Innovative Drugs - Innovative drugs, also known as original research drugs, are defined as drugs with independent intellectual property patents and new chemical structures with clinical value [2] - The innovative drug sector has seen a record high in licensing agreements, with 57 license-out transactions in the first five months of 2025, a 23.9% increase year-on-year, and a total transaction value of $48.69 billion, up 121% from the previous year [3] Group 2: Revenue Growth and Profitability - Overall revenue for innovative drug companies has steadily increased over the past seven years, with net profits also growing rapidly, indicating a trend towards profitability among leading companies [4][5] Group 3: Policy and Regulatory Support - The introduction of a commercial insurance directory for innovative drugs marks a significant policy shift, allowing for diverse payment mechanisms and supporting the inclusion of innovative drugs in reimbursement [6] - Regulatory improvements include the reintroduction of the fifth set of standards for the Sci-Tech Innovation Board, which focuses on market value and R&D rather than revenue and profit, facilitating easier financing for biotech firms [7] - The NMPA has proposed to reduce the review time for clinical trial applications to 30 working days, halving the previous requirement [7] Group 4: Financing Environment - The innovative drug sector is characterized by long development cycles and high investment costs, making it sensitive to changes in financing conditions. Recent decreases in social financing costs and improved liquidity have created a favorable environment for the sector [8] Group 5: Trading Mechanisms - The innovative drug-related ETFs in the Hong Kong market allow for T+0 trading, enhancing capital utilization and trading flexibility for investors [9]